Dr.Ogita + OK-432 Therapy
Lymphatic malformations (formerly called "lympangiomas") are localized malformations of the lymphatic system, which normally appear by the age of five years old. Lymphatic malformations most frequently affect the neck and make breathing difficult by compressing the respiratory tract and trachea, causing the patients to death due to dyspnea. Although histologically benign, lymphatic malformations may extend to the surrounding tissues like a malignancy. Due to this, complete surgical excision without damage to surrounding vital structures and also without cosmetic problems was almost impossible. With incomplete excision, disease recurrence was very high. But surgical excision has been the treatment of choice for years as no appropriate replacement was available, placing a heavy psychological and economical burden on the patients.
In 1986 Dr. Shuhei Ogita, a pediatric surgeon of Kyoto Prefectural University of Medicine, found OK-432 therapy, where OK-432 (tradename: Picibanil), which was then being used as an anti-cancer drug, is injected into the cyst and it reduces the size of, or completely removes the lymphatic malformation. Since its initial use, OK-432 therapy has become highly commended as success stories increased and further research promoted its effect. OK-432 therapy soon became a standard treatment procedure for lymphatic malformations in Japan.